PT2654769T - Peptido anti tumoral derivado de uma região determinante de complementaridade de um anticorpo monoclonal humanizado para o transportador napi2b - Google Patents

Peptido anti tumoral derivado de uma região determinante de complementaridade de um anticorpo monoclonal humanizado para o transportador napi2b

Info

Publication number
PT2654769T
PT2654769T PT118495712T PT11849571T PT2654769T PT 2654769 T PT2654769 T PT 2654769T PT 118495712 T PT118495712 T PT 118495712T PT 11849571 T PT11849571 T PT 11849571T PT 2654769 T PT2654769 T PT 2654769T
Authority
PT
Portugal
Prior art keywords
monoclonal antibody
complementarity determining
determining region
humanized monoclonal
peptide derived
Prior art date
Application number
PT118495712T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Recepta Biopharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepta Biopharma S A filed Critical Recepta Biopharma S A
Publication of PT2654769T publication Critical patent/PT2654769T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT118495712T 2010-12-14 2011-12-14 Peptido anti tumoral derivado de uma região determinante de complementaridade de um anticorpo monoclonal humanizado para o transportador napi2b PT2654769T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
PT2654769T true PT2654769T (pt) 2020-07-16

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118495712T PT2654769T (pt) 2010-12-14 2011-12-14 Peptido anti tumoral derivado de uma região determinante de complementaridade de um anticorpo monoclonal humanizado para o transportador napi2b

Country Status (8)

Country Link
US (2) US9193797B2 (enExample)
EP (1) EP2654769B1 (enExample)
JP (1) JP6087289B2 (enExample)
BR (1) BR112013015001B1 (enExample)
CO (1) CO6721014A2 (enExample)
ES (1) ES2804476T3 (enExample)
PT (1) PT2654769T (enExample)
WO (1) WO2012080822A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016013258A2 (pt) * 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
BR112019026332A2 (pt) * 2017-07-01 2020-07-21 Recepta Biopharma S A métodos e peptídeos imunomodulatórios para modular o sistema imunológico em um indivíduo
IL273252B2 (en) * 2017-09-20 2024-03-01 Mersana Therapeutics Inc Compositions and methods for predicting response to napi2b-targeted therapy
CA3188501A1 (en) 2020-08-07 2022-02-10 Todd Golub Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
KR102822203B1 (ko) 2020-12-29 2025-06-18 삼성전자주식회사 전력 공급 장치를 이용하여 오디오 출력 장치를 찾는 방법 및 그 전력 공급 장치
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5827498A (en) * 1994-06-07 1998-10-27 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
WO2012080822A9 (en) 2016-08-11
BR112013015001A2 (pt) 2017-12-19
WO2012080822A2 (en) 2012-06-21
JP2014510699A (ja) 2014-05-01
US9896512B2 (en) 2018-02-20
CO6721014A2 (es) 2013-07-31
EP2654769A4 (en) 2017-10-25
BR112013015001A8 (pt) 2018-04-17
US20130315902A1 (en) 2013-11-28
US9193797B2 (en) 2015-11-24
US20160108132A1 (en) 2016-04-21
JP6087289B2 (ja) 2017-03-01
BR112013015001B1 (pt) 2021-10-13
EP2654769B1 (en) 2020-04-15
ES2804476T3 (es) 2021-02-08
EP2654769A2 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
HUS2500028I1 (hu) XII/XIIa faktor elleni gátló monoklonális ellenanyagok és alkalmazásaik
EP2734551A4 (en) HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODY VARIANTS
IL245274B (en) Monoclonal antibodies against the 2her epitope
ZA201306589B (en) Humanised anti ctla-4 antibodies
IL216002A (en) An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd
LT3789038T (lt) Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
ZA201400768B (en) Interleukin-31 monoclonal antibody
PT2654769T (pt) Peptido anti tumoral derivado de uma região determinante de complementaridade de um anticorpo monoclonal humanizado para o transportador napi2b
SG11201401857WA (en) Humanized antibodies that recognize alpha-synuclein
EP2542262A4 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20
PL2663865T3 (pl) Szczególne przeciwciała monoklonalne A1AT do wykrywania endometriozy